Video

Customizing Imaging Based on Calcitonin Levels in MTC

For High-Definition, Click

The role of imaging before surgery for patients with medullary thyroid cancer relies heavily on the initial calcitonin level. Additionally, this level can be used to suggest prognosis and an appropriate surgical procedure.

In some cases, believes Eric J. Sherman, MD, imaging can be reserved until after surgery. However, utilizing imaging before surgery helps determine nodal involvement, distribution, and the presence of mediastinal disease, notes Lori J. Wirth, MD. Ultrasounds are often utilized before surgery but often miss high retropharyngeal, deep paratracheal, and mediastinal lymph node involvement.

The decision concerning whether to utilize ultrasound, CT, or MRI can be guided by the calcitonin level, explains R. Michael Tuttle, MD. If levels are 30 or 40 with a small nodule, imaging may not be necessary. However, if levels are in the hundreds, lymph node involvement is more likely, requiring a CT scan or MRI of the neck and chest to ensure the proper surgical procedure is performed. Steven I. Sherman, MD, adds that if the calcitonin level is around 500, cross-sectional imaging of the neck, chest, and liver should be performed prior to surgery to diagnose distant disease.

In addition to staging, calcitonin levels may help indicate prognosis and whether a cure is possible, remarks Tuttle. If levels are 3,000 to 5,000 a biochemical cure is unlikely. In these situations, it may be appropriate to bypass a surgery, to avoid unneeded comorbidities.

Related Videos
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.